We also introduce a mathematical correction for the BCR-ABL1 assay that could help homogenizing the use of the ABL1 as a control gene. In this review, we discuss the importance of the BCR-ABL1 assay, and we highlight the growing importance of BCR-ABL1 dynamics. Patients treated with TKIs require sensitive monitoring of BCR-ABL1 transcripts with quantitative real-time polymerase chain reaction (qRT-PCT), which has become an essential part of managing patients with CML. Since the introduction of imatinib, the first TKI, several other TKI have been approved that further broadened the arsenal against CML. The advent of tyrosine kinase inhibitors (TKI) represents a landmark in the treatment of CML, that has led to tremendous improvement in the remission and survival rates. The BCR-ABL1 codes for an aberrantly functioning tyrosine kinase that drives the malignant proliferation of the founding clone. The Philadelphia chromosome contains a fusion gene called BCR-ABL1. Orsola-Malpighi University Hospital, University of Bologna, Bologna, ItalyĬhronic myelogenous leukemia (CML) is a malignancy of the myeloid cell lineage characterized by a recurrent chromosomal abnormality: the Philadelphia chromosome, which results from the reciprocal translocation of the chromosomes 9 and 22. 5Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L.4Department of Hematology, Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.3Department of Mathematics, Babes Bolyai University, Cluj Napoca, Romania.2Department of Hematology, Ion Chiricuta Clinical Research Center, Cluj Napoca, Romania.
1Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.Vlad Moisoiu 1, Patric Teodorescu 1,2 †, Lorand Parajdi 3, Sergiu Pasca 1 †, Mihnea Zdrenghea 1, Delia Dima 2, Radu Precup 3, Ciprian Tomuleasa 2,4 * and Simona Soverini 5
0 kommentar(er)
